Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company focused on T cell‑redirecting cancer immunotherapies, with a strong emphasis on precision targeting of PRAME. The IMTX news feed on Stock Titan aggregates company‑issued updates, investor communications and regulatory disclosures so readers can follow how Immatics’ pipeline and corporate strategy evolve over time.
Recent Immatics news has highlighted multiple strands of its PRAME franchise. These include data from the Phase 1b program of anzu‑cel (anzutresgene autoleucel, formerly IMA203) PRAME cell therapy in metastatic melanoma and uveal melanoma, the ongoing randomized Phase 3 SUPRAME trial in previously treated advanced cutaneous melanoma, and new results from the second‑generation PRAME cell therapy IMA203CD8 in advanced solid tumors such as ovarian carcinoma, melanoma and synovial sarcoma.
Investors and observers can also track updates on Immatics’ TCR Bispecific pipeline, including IMA402, a PRAME‑directed bispecific, and IMA401, a MAGEA4/8‑directed bispecific. Company releases describe Phase 1a dose escalation data, favorable tolerability at recommended dose ranges, and deep, durable responses in heavily pretreated patients with a range of solid tumors. Financial results, underwritten equity offerings, leadership appointments and collaboration milestones with partners such as Moderna are also reported in the company’s quarterly and transaction‑related news.
By following IMTX news, readers gain context on clinical trial progress, interim data readouts, financing activities and strategic shifts that shape Immatics’ development path in PRAME‑positive cancers and other solid tumors. Bookmark this page to access a consolidated stream of press releases and related announcements as they are published.
Immatics N.V. (NASDAQ: IMTX) reported significant advancements in its ACTengine® IMA203 TCR-T immunotherapy, showing a 50% confirmed objective response rate (cORR) across various solid tumors in an interim update. The company plans to prioritize 1st and 2nd-generation monotherapy treatments in pivotal trials by 2H 2023. Progress includes the establishment of an in-house GMP manufacturing facility scheduled for 2024, enhancing production capacity. Financially, total revenue surged to €172.8 million in 2022, marking a substantial increase from €34.8 million in 2021, with a net profit of €37.5 million.
Seamless Therapeutics has secured
Immatics N.V. (NASDAQ: IMTX) reported an interim clinical update on ACTengine® IMA203, noting a confirmed objective response rate (cORR) of 50% from Phase 1 trials. The initial results indicate promising efficacy across various solid tumors, including melanoma and ovarian cancer. The company also announced the ongoing treatment of patients with its 2nd generation TCR-T candidate, IMA203CD8, and plans to start a Phase 1/2 trial for TCER® IMA402 in 2023. Financially, Immatics has €309.3 million in cash, projected to fund operations into 2025, and reported a revenue increase to €15.1 million for Q3 2022.
Immatics N.V. has announced a public offering of 10,905,000 ordinary shares priced at $10.09 per share, aiming to raise approximately $110 million in gross proceeds. The offering is expected to close on October 12, 2022, contingent on customary closing conditions. Notable investors include Armistice Capital, Dellora Investments, and Wellington Management. Jefferies and SVB Securities are serving as joint book-running managers for this offering.
Immatics announced promising clinical data for IMA203, a TCR-T therapy targeting PRAME in solid tumors. In a Phase 1 trial, 27 patients were treated, showing a 50% confirmed objective response rate (cORR) at high doses. Specifically, in Phase 1b, 80% of 5 patients experienced ongoing responses across various solid tumors, including melanoma and ovarian cancer. IMA203 demonstrated manageable tolerability with no dose-limiting toxicities. Future data releases and further expansion cohorts are anticipated in 2023, enhancing the outlook for IMA203 and its potential impact on cancer treatments.
Immatics N.V. (NASDAQ: IMTX) announced promising preclinical results for its T cell engaging receptor IMA402, targeting the cancer-associated antigen PRAME, at the ESMO Congress 2022. IMA402 demonstrated enhanced anti-tumor activity in vivo and favorable safety profiles in vitro. With a half-life of over one week, it is expected to allow for effective dosing in patients. The Phase 1/2 clinical trial is set to commence in 2023, with the submission of the Clinical Trial Application planned for Q2 2023, positioning IMA402 as a significant advancement in TCR bispecific therapies.
Immatics announced the initiation of patient treatment in its Phase 1b expansion cohort C for IMA203CD8, a 2nd generation TCR-T monotherapy that targets PRAME in solid tumors. This treatment employs a proprietary CD8αβ co-receptor, enhancing T cell activation. Preclinical results indicated improved anti-tumor activity. The cohort aims to assess IMA203CD8's safety and initial efficacy, with 24 patients expected to be enrolled. Interim data from previous trials showed a 50% objective response rate across various solid tumors. The study is part of a broader multi-cohort strategy.
Immatics N.V. (NASDAQ: IMTX) has initiated patient enrollment in three Phase 1b cohorts for its ACTengine® TCR-T cell therapy targeting PRAME. A multi-program collaboration with Bristol Myers Squibb includes a $60 million upfront payment and potential milestone payments nearing $700 million. The company's financial results for Q2 2022 show a revenue increase to €17.2 million and a net loss reduction to €14.0 million. Cash reserves total €324.4 million, funding operations through the second half of 2024. Expanded collaborations and clinical trials mark continued growth in cancer immunotherapy development.
Bristol Myers Squibb (NYSE:BMY) reported Q2 2022 revenues of $11.9 billion, a 2% year-over-year increase, or 5% when adjusted for foreign exchange. GAAP EPS rose 40% to $0.66, while non-GAAP EPS reached $1.93, mainly impacted by ($0.14) per share from Acquired IPRD charges. 11% revenue growth was noted in in-line products. The company reaffirmed non-GAAP EPS guidance for 2022 while adjusting GAAP EPS guidance. Additionally, they announced plans to acquire Turning Point Therapeutics (NASDAQ:TPTX) for $4.1 billion, expanding their precision oncology portfolio.
Immatics reported significant advancements in its clinical programs, specifically in its IMA203 and IMA401 trials. Patients have commenced treatment in two Phase 1b cohorts, with IND approval for the third cohort. Furthermore, a strategic partnership with Bristol Myers Squibb includes a $60 million upfront payment and potential milestones exceeding $700 million per program. Financially, Immatics reported a net income of €85.7 million for Q1 2022, a notable increase from a loss of €22.8 million in Q1 2021, largely due to collaboration revenue recognition.